CDK Inhibitor Compounds for Selective CDK2/4/6 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective CDK4/6 inhibitors to treat cell proliferative disorders such as cancer, as the regulation of the G1 restriction point by these kinases is altered in a broad spectrum of human tumors.
Innovation Solution
Development of compounds that inhibit CDK2, CDK4, and CDK6 activity, including pharmaceutically acceptable salts and stereoisomers, which demonstrate strong anti-proliferation activities and selective brain penetration, and are used in pharmaceutical compositions for cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule CDK4/6 inhibitors are used to treat cancer, then anti-proliferation activity is improved, but selectivity between CDK2, CDK4, and CDK6 inhibition is worsened
Solution Approach 1:
The patent applies local quality by designing specific molecular features at particular positions of the inhibitor structure. The core structure with specific substituent patterns at defined positions (R1-R6 groups) creates localized interactions that differentiate binding affinity for CDK2, CDK4, and CDK6, enabling selective inhibition while maintaining anti-proliferation activity.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters (substituent types, positions, and configurations) of the small molecule structure. By modifying molecular weight, hydrophobicity, and steric parameters through different R group configurations, the invention optimizes both potency and selectivity profile across the CDK family.
2Adaptability or versatility
If broad-spectrum CDK inhibition is achieved, then treatment efficacy across multiple cancer types is improved, but off-target effects and toxicity are worsened
Solution Approach 1:
The patent applies dynamics by creating a flexible molecular framework where the core structure can adapt to different CDK isoforms while maintaining selective binding. The dynamic substituent patterns allow the inhibitor to adjust its conformation and interaction profile based on the specific CDK target, enabling broad-spectrum activity with controlled off-target effects through rational design.
Data Source
AI summary
The invention provides a compound represented by represented by the following strutural formula:or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.